Trial · NCT07877818
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
NCT07877818, Phase 3, Recruiting, AstraZeneca
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC. Trials, record NCT07877818. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07877818
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
- NCT number
- NCT07877818
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 140 participants, estimated
- Lead sponsor
- AstraZeneca
- Conditions
- Gastric, Esophagogastric Junction
- Interventions
- FLOT Chemotherapy, Durvalumab
- First posted
- 2026-10-16
- Last updated
- 2026-11-06
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To compare Arm A relative to Arm B on pCR rate | Up to 24 months after the last participant is randomized | pCR rate is defined as the proportion of participants who have no residual viable tumour in the resected specimens and as determined by central pathology review. |
| Secondary | To compare Arm A relative to Arm B on event-free survival at 24 months (EFS24) | Up to 24 months after the last participant is randomized | EFS24 is the proportion of participants alive and event free 24 months after randomization, according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 per Investigator assessment and/or locally by pathology testing. |
| Secondary | To compare Arm A relative to Arm B on overall survival (OS) | Up to 24 months after the last participant is randomized | Overall survival is length of time from randomization until the date of death due to any cause. |
| Secondary | To compare Arm A relative to Arm B on event-free survival (EFS) | Up to 24 months after the last participant is randomized | EFS is defined as the time from randomization to the following, according to RECIST 1.1 per Investigator assessment and/or locally by pathology testing: 1. Progression that precludes surgery or requires non-protocol therapy, 2. Local or distant recurrence or progression of disease, or 3) Death due to any cause. |
| Secondary | To compare Arm A relative to Arm B on the rate of complete resection (R0) | Up to 24 months after the last participant is randomized | R0 resection (complete resection) rate is the proportion of participants who have a confirmed complete resection as assessed by pathology review. |
| Secondary | To compare Arm A relative to Arm B on metastasis-free survival (MFS) and disease-specific survival (DSS) | Up to 24 months after the last participant is randomized | MFS is the time from randomization until the development of metastasis using RECIST 1.1 or death due to any cause. • DSS is the time from randomization untildeath due to GC/GEJC. |
| Secondary | To compare Arm A relative to Arm B on disease-free survival (DFS) in participants who undergo R0 resection surgery | Up to 24 months after the last participant is randomized | DFS is defined as the time from first post-surgery scan until disease recurrence, using RECIST 1.1, or death due to any cause. |
| Other | To assess the safety and tolerability of Arm A as compared to Arm B in participants with GC/GEJC | Up to 24 months after the last participant is randomized | Safety and tolerability will be evaluated in terms of adverse events (AEs) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07877818
GET https://conductscience.org/api/trials/v1/NCT07877818/registered